Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford is one of 28 sites that will benefit from over £160 million awarded over five years to expand early phase clinical research for the benefit of NHS patients.

Oxford Experimental Medicine Clinical Research Facility

The National Institute for Health Research (NIHR) announced the funding for its Clinical Research Facilities (CRF) on Monday 28 February. The NIHR Oxford Clinical Research Facility is one of five new facilities and will be hosted by Oxford University Hospitals (OUH) NHS Foundation Trust.

CRFs support the delivery of early translational and experimental medicine research, from studies testing new treatments in patients for the very first time (first-in-human trials) through to early safety and efficacy trials (Phase II trials). They provide dedicated purpose-built facilities and expertise for the delivery of high-intensity studies funded by the NIHR, charities, the life sciences industry and other organisations.

The Oxford Experimental Medicine Clinical Research Facility (EMCRF), based at the Churchill Hospital, will act as the hub of the Oxford CRF. It provides a resource for early phase, experimental research across the University of Oxford’s Medical Sciences Division. The EMCRF is central to the clinical translational strategy of the Oxford Biomedical Research Centre (BRC), providing service to all specialities in the BRC Themes.

Read the full story on the NIHR Oxford Biomedical Research Centre website

Read about the Oxford Health Clinical Research Facility which was also awarded funding

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.